The present invention relates to novel 1-thia-dibenzoazulene derivatives of the formula (I), wherein X individually denotes a hetero atom -O- or -S-; Y and Z independently from each other individually denote a fragment of the formula (II) to their pharmacologically acceptable esters, salts and solvates, to processes and intermediates for the preparation thereof, to a process for preparing pharmaceutical formulations for the treatment of inflammatory diseases and conditions and to the use thereof in the treatment of inflammatory diseases and conditions in humans and animals. These compounds inhibit tumour necrosis factor-α(TNF-(α) production and interleukin-1 (IL-1) production and exhibit an analgetic action.